Payment overview · 2025
General Payments
$97.96
3 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Ralph Berg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1013947555
Verified facts
What the public records show
CMS Open Payments records show Daniel Ralph Berg, MD received $97.96 in general payments during 2025 across 3 reported records.
Braeburn Inc. accounted for 61.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Braeburn Inc. | Unresolved — no canonical attribution shown | $60.41 | 61.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.55 | 38.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.96 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $60.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.55 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 592 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 350 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 329 | 42 |
| Alprazolam | Alprazolam | 327 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 45 |
| Gabapentin | Gabapentin | 227 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 53 |
| Furosemide | Furosemide | 159 | 33 |
| Metformin Hcl | Metformin Hcl | 151 | 37 |
| Lisinopril | Lisinopril | 149 | 42 |
| Trulicity | Dulaglutide | 144 | 24 |
| Trazodone Hcl | Trazodone Hcl | 132 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 31 |
| Famotidine | Famotidine | 120 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 21 |
| Losartan Potassium | Losartan Potassium | 115 | 25 |
| Farxiga | Dapagliflozin Propanediol | 114 | 20 |
| Meloxicam | Meloxicam | 112 | 28 |
| Potassium Chloride | Potassium Chloride | 111 | 21 |
| Omeprazole | Omeprazole | 109 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 14 |
| Clonazepam | Clonazepam | 97 | 15 |
| Jardiance | Empagliflozin | 89 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 24 |
| Eliquis | Apixaban | 84 | 18 |
| Metformin Hcl Er | Metformin Hcl | 84 | 24 |
| Ozempic | Semaglutide | 84 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 18 |
| Carvedilol | Carvedilol | 82 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 79 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 70 | 12 |
| Valsartan | Valsartan | 69 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 15 |
| Spironolactone | Spironolactone | 65 | 20 |
| Tramadol Hcl | Tramadol Hcl | 61 | 11 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 60 | 19 |
| Naproxen | Naproxen | 59 | 13 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 56 | suppressed |
| Diazepam | Diazepam | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 12 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Prednisone | Prednisone | 47 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 12 |
| Glimepiride | Glimepiride | 39 | 11 |
| Linzess | Linaclotide | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 12 |
| Celecoxib | Celecoxib | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 22 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Belsomra | Suvorexant | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 15 |
| Clotrimazole | Clotrimazole | 28 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 17 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Depakote | Divalproex Sodium | 13 | suppressed |
| Dronabinol | Dronabinol | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sublocade | Buprenorphine | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.96 · 3 records | Braeburn Inc. | BRIXADI, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error